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Chronic kidney disease and its prevention in India. Chronic kid-
ney disease (CKD) is an important, chronic, noncommunicable
disease epidemic that affects the world, including India. Be-
cause of the absence of a renal registry in India, the true magni-
tude of CKD/end-stage renal disease (ESRD) is unknown. Two
community-based studies, although methodologically different,
have shown a prevalence of chronic renal failure of 0.16% and
0.79%. The cost of maintenance hemodialysis for a single ses-
sion varies between US $10 to 40 between government-run and
private hospitals. The average cost of erythropoetin is approx-
imately US $150 to 200 per month. The cost of chronic am-
bulatory peritoneal dialysis with “Y” set at 3 exchanges per
week, which most patients in India do, is US $400 per month.
The cost of a renal transplant (RT) procedure is approximately
US $700 to 800 in the government sector and US $6000 in the
private sector. The cost of immunosuppression with basic triple
immunosuppression drugs (cyclosporine, steroid, and azathio-
prin) is US $250 per month. There are hardly any state-funded
medical treatment and medical insurance facilities for CKD and
ESRD patients in India. India has nearly 700 nephrologists and
approximately 400 dialysis units with 1000 dialysis stations, with
the majority being in the private sector. A maximum of 2% of
patients can be subjected to maintenance hemodialysis. Until
now, approximately 3000 patients have been initiated on chronic
ambulatory peritoneal dialysis. India has approximately 100 RT
centers, mostly in private setup, and not more than 3000 to 4000
RTs are performed annually. Thus, only 3% to 5% of all pa-
tients with ESRD in India get some form of renal replacement
therapy. Thus, planning for prevention of CKD on a long-term
basis is the only practical solution for India.
It appears that even in India, diabetes and hypertension are
responsible for 40% to 50% of all cases of chronic renal failure.
Screening for these 2 diseases and CKD is simple and easy to
perform. The best approach will be to start screening for CKD
in a high-risk group, like first-degree relatives of patients with
diabetes, hypertension, and CKD, and simultaneously making
a platform to run the program through the existing health care
system of the country. The key issue of funding the program
needs to be explored. Initial funding may come from inter-
national agencies like the World Health Organization, World
Bank, and International Society of Nephrology, along with sup-
port from the country itself. Ultimately, funding has to be sus-
tained from our own existing health care system.
Chronic kidney disease (CKD) has become one of the
most important, chronic, noncommunicable disease epi-
Key words: CKD, prevention, India.
C© 2005 by the International Society of Nephrology
demics in the world, including India. It is clear that treat-
ment of CKD and its advanced stage, that is, end-stage
renal disease (ESRD), is consuming a huge proportion of
health resources in most of the country, and in India it is
beyond the reach of the average Indian. Thus, it is crucial
that prevention of CKD become an important goal of the
medical fraternity, government, and public at large in any
country, including India.
MAGNITUDE OF CKD
For a long time it was presumed that nearly 100,000 new
patients with ESRD required renal replacement therapy
(RRT) every year. In the absence of a renal registry in
India, the true magnitude of CKD/ESRD is not known.
Most of the data related to CKD are hospital-based, from
few tertiary care centers, which document the spectrum
of etiology for CKD rather than the magnitude of the
problem. There are only 2 population-based studies in
India commenting on the magnitude of CKD. Mani [1]
from Chennai in south India, while, in general, initiating
a prevention program (more so for diabetes and hyper-
tension at the community level in a rural area with a to-
tal population 25,000), reported a prevalence of chronic
renal failure (CRF) of 0.16% and other renal diseases
(short of CRF) in 0.7% of patients. In this study, a pre-
ventive and social health worker traveled from house
to house, where each family member was asked to fill
out a brief questionnaire related to renal illness. Urine
was examined for albumin and reducing substance with
sulphosalicylic acid and benedict solution, respectively.
However, all patients were not evaluated with blood tests
for urea/creatinine, and only those who had some abnor-
mality in the urine test/blood pressure and/or a positive
response to a questionnaire were subjected to a blood
test for urea/creatinine.
The second study, which has been accepted for publica-
tion and is currently in press [2], was done by our group.
Four thousand nine hundred and seventy-two patients in
urban communities in Delhi were screened for blood urea
and creatinine estimation with a specific aim to find out
the prevalence of CRF. In addition, other information re-
lated to kidney disease, diabetes, and hypertension was
also collected. A thorough history and a detailed physical
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examination, including blood pressure measurement as
per our questionnaire, were obtained from each patient
in the family that was 16 years of age and older. After
this, a fresh mid-stream urine sample was examined for
albumin and sugar with a dipstick. Of the 4972 patients
evaluated, prevalence of CRF, defined as serum creati-
nine >1.8 mg% (upper limit of our laboratory) persistent
for more than 3 months in the absence of any reversible
factor, was found to be 0.79% or 7852 per million pop-
ulation. This figure is much higher than the figure in the
study from Mani [1]. In the absence of a registry related
to renal diseases, these are the only 2 community-based
data available from India. A 1998 report from the Third
National Health and Nutrition Examination Survey, con-
ducted from 1988 to 1994 in the United States, estimated
that if we take serum creatinine >1.7 mg% as the cutoff
for CRF—a value close to 1.8 mg%, which is what we
have taken as the cutoff for defining CRF in the present
study—then during the same period, there were 12 times
more CRF cases than ESRD cases [3]. Extrapolating this
information, if we take patients with ESRD to be 10% of
patients with CKD, from our own study, the prevalence
of ESRD comes out to be 785 per million population in
India.
COST OF THERAPY OF CKD IN INDIA
Not only is the magnitude of the CKD/ESRD problem
high in India, but the cost of RRT is also exuberant. With
India’s gross national product being US $470 and the av-
erage expanse of various state and central government on
health cost being approximately US $7, the government
expects that the cost of RRT should be borne by the indi-
vidual himself. However, there is some support from the
government to a small number of patients, and the cost
of therapy in this government setup is significantly sub-
sidized. Cost of maintenance hemodialysis (MHD) for
a single session varies between US $10 to 40 between
government-run and private hospitals. This excludes the
cost of erythropoetin, which is approximately US $150
to 200 per month (the majority of patients receives 4000
to 6000 units of erythropoetin every week). The cost of
continuous ambulatory peritoneal dialysis (CAPD) with
“Y” set at 3 exchanges per week, which most patients
in India do, is US $400 per month. The cost of erythro-
poietin is similar to MHD. The cost of renal transplant
(RT) varies between the government sector and the pri-
vate sector. The cost of an RT procedure is US $700 to
800 in the government sector and US $6000 in the private
sector. The cost of immunosuppression with basic triple
immunosuppression drugs (cyclosporine, steroid, and
azathioprin) is US $250 per month; this figure may go
down if cyclosporine is withdrawn and the patient is only
given steroids and azathioprin. Thus, on a long-term ba-
sis, RT still remains a cheaper modality of treatment for
ESRD in India compared with both MHD and CAPD.
With competition, local manufacturing of CAPD bags
and immunosuppressive medications, and a decrease in
the import duties on various items, the cost of RRT is com-
ing down and may go down further. However, with the
availability of an automated cycler for night peritoneal
dialysis and newer immunosuppressive medications like
mycophenolate mofetil, rapamycin, interleukin-2 recep-
tion antibodies, and so forth, the cost of therapy can in-
crease also.
In the absence of state-funded medical treatment and
medical insurance facilities for patients with CKD/ESRD,
there are various sources from which patients get money
for treatment. In one study, it was concluded that 63% had
help from their employer or charity, 26% took loans, and
34% sold assets or pooled their family resources. Obvi-
ously, many have more than one source [4]. In spite of all
these options, only 3% to 5% of all patients with ESRD in
India get some form of renal replacement therapy (RRT).
It is not at all difficult to imagine what happens to the
rest of them. In all major studies of ESRD from differ-
ent parts of India (mostly hospital-based studies), men
in their 30s were the most common group affected by
the disease [5–8]. Thus, an employed patient with ESRD
must search for finances for his treatment, not only for
direct treatment cost but also for the indirect cost of a loss
of job/working days, which is enormous. Thus, many call-
ing CRF a “chronic revenue failure” is not inappropriate,
especially in the Indian context.
FACILITIES FOR RRT IN INDIA
Aside from the cost of RRT, availability of RRT is also
an issue in India. India has nearly 700 nephrologists and
approximately 400 dialysis units with 1000 dialysis sta-
tions [9], with the majority being in the private sector.
The government sector cannot afford to provide MHD,
and thus only runs RT-oriented dialysis. The majority of
hospitals do 2 shifts of dialysis. Even though we take all
stations doing MHD, a maximum of 2% of patients can be
subjected to MHD. Although the first patient on CAPD
in India was initiated in 1990, until now only approxi-
mately 3000 patients have been initiated on this modality
of therapy [10]. Thus, although CAPD is becoming pop-
ular and is being used more frequently, it still has a long
way to go. Generally, CAPD is used as a last resort as
RRT in India. Regarding RT, India has approximately
100 RT centers, most of which are in private setup. No
more than 3000 to 4000 RTs are done annually [11]. In
the absence of a well-organized cadaver program, living
donors constitute the major donor source in India and,
unfortunately, a large number of them are unrelated. In
spite of an organ transplant bill being passed in 1994, un-
til now only approximately 550 cadaver RTs have been
performed in India. Thus, taking altogether (3000 RT +
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maximum 5000 MHD + maximum 300 CAPD per year),
approximately 3.5% of patients with ESRD get any sort
of RRT.
Therefore, it is clear that considering the magnitude
of the problem of CKD/ESRD in India and the avail-
ability of RRT and its cost implications, India cannot af-
ford to provide care for the majority of its patients with
CKD/ESRD. Thus, planning for the prevention of CKD
on a long-term basis is the only practical solution for In-
dia, just as it would be for any other country. Before any
preventive program for a chronic illness (like CKD) on
community basis is planned, a few other issues need to be
addressed [1]: (1) Is the disease easy to detect? (2) Can
the disease be easily prevented? (3) Is the cost of pre-
vention less than the treatment? (4) Can the preventable
program be sustainable?
ETIOLOGY OF CKD IN INDIA
Because CKD is a clinical syndrome, one has to un-
derstand its etiology if one wishes to plan a preventive
program at the community level. As discussed previously,
there are only 2 community-based data on CRF in India.
Dr. Mani’s study has not published, in detail, the etiology
of CRF in 0.16% of his patients with CRF in the commu-
nity. Our own unpublished study, although not planned
to study the etiology of CRF, showed that of the 0.79%
patients with CRF, 41% were due to diabetes, 22% to hy-
pertension, and 16% to chronic glomerulonephritis. Thus,
diabetes and hypertension constituted 63% of all cases
of CRF in our study. One may argue that the etiology
of hypertension as a cause of CRF is controversial, and
many other diseases causing CRF may be attributed to
hypertension, because hypertension is a common early
manifestation in many other diseases causing CRF. If we
compare other hospital-based studies from India regard-
ing the etiology of CRF/ESRD [5, 6, 8], the data are vari-
able (Fig. 1). Nearly 25% of all patients with ESRD in
these studies had diabetes and 6% to 13% had hyperten-
sion. However, we must realize that these are tertiary-
care, hospital-based studies and do not represent the
community. For example, in all of these studies, the mean
age of patients was early 40s, whereas in our community-
based study, the mean age of patients with CRF was 59
years. There may be a bias in favor of younger persons
attending hospitals. This can cause differences in the eti-
ology of patients with CRF attending hospitals compared
with patients in the community. Further, if we see that pa-
tients with CRF caused by diabetes and hypertension only
in one of these studies [8], the mean age of patients was
nearly 50 years. Also, in the same study, in patients over
40 years of age, diabetes and hypertension comprised
more than 55% of cases of CRF, a pattern similar to what
is seen in our community-based study. All of this suggests
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Fig. 1. Major causes of chronic renal failure in India.
sible for at least nearly 50% of all cases of CRF. With
the increasing problem of diabetes in India, the absolute
number of diabetic patients with CKD/ESRD is likely to
be enormous. Thus, if we concentrate on these 2 diseases
only on a community basis for a prevention program for
CKD, we may be able to prevent a large number of CKD
cases.
It is obvious that clinical examination for blood pres-
sure, urine examination for protein and sugar, spot urine
for albumin/creatinine, and blood test for sugar and crea-
tinine are simple tests to perform, and these are the tests
required for the diagnosis and basic management of CKD
and its 2 major etiologies—diabetes and hypertension.
Further, it is also established that if we diagnose CKD
early, its progression to ESRD can be retarded signifi-
cantly by nonmedical and medical therapy, quality of life
can be improved, and, once the patient reaches ESRD, its
outcome of therapy is better. From western data, it is also
known that, economically, prevention is cheaper than the
therapy for CKD/ESRD.
STRATEGIES FOR THE IMPLEMENTATION OF
A PREVENTION PROGRAM IN INDIA
Implementation is the most difficult issue in a CKD
prevention program in any country, more so in a large
country like India. Programs like those in the Aborig-
inal communities in Australia led by Hoy [12] are not
applicable in India, because there is no such small com-
munity that has a very high risk of CKD that can be tar-
geted. Programs like those being done by Ramirez [13] in
a small country like Singapore, in which the whole coun-
try is approached, will also not be applicable in India be-
cause of obvious logistics of population size. Something in
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between needs to be started in India, where a program has
yet to begin. Mani’s program [1] looks quite encouraging,
but adopting this for the whole country is still far away
and also needs to be accepted by health care policy mak-
ers. At the individual level, it may not be possible. Until
that happens, the best approach will be to start screening
for CKD in high-risk groups, like first-degree relatives of
patients with diabetes and hypertension and patients with
CKD. There are some studies, which have demonstrated
that first-degree relatives of these high-risk groups have a
higher chance of having CKD. In a recent study, the long-
term risk of developing overt nephropathy in type 1 dia-
betes mellitus was found to be 72% in diabetic relatives
of nephropathy patients, compared with 25% among dia-
betic patients whose relatives lacked kidney disease [14].
It is increasingly clear that ESRD clusters in families. This
familial aggregation is pronounced in nephropathies as-
sociated with hypertension [15] and types 1 and 2 diabetes
mellitus [16, 17]. This clustering occurs in excess of that
expected from the prevalence of hypertension and dia-
betes mellitus within families [18]. Another study in 4365
incident ESRD patients in the southeastern United States
revealed that 14% of white patients and 23% of black
patients had first- or second-degree relatives with ESRD
[17]. The prevalence of subclinical nephropathy in these
families is likely to be far greater. We are aware of 2 im-
portant prevention programs, which have demonstrated
the importance of screening CKD in families of high-risk
groups: the Kidney Early Evaluation Program (KEEP)
[19], sponsored by the National Kidney Foundation, and
the Family History of ESRD program by the Southeast-
ern Kidney Council/ESRD Network in the United States
[20]. While starting a prevention program from a high-risk
group, we should also simultaneously use other strategies
that are relevant from a point of prevention of CKD on
a long-term basis.
In my opinion, the following simultaneous strategies
currently need to be adopted for starting this program:
(1) Starting awareness of CKD in the medical commu-
nity and among policy makers and the community at
large through the print media, electronic media, radio,
and pamphlet distribution at appropriate forums like
hospitals, schools, banks, shopping malls, and so forth.
(2) Planning multicentric studies for finding the preva-
lence of CKD and its causes in 4 corners of the country.
(3) Starting the screening of first-degree relatives of pa-
tients with CKD, diabetes, and hypertension in an orga-
nized manner, possibly starting in the urban area of the
country through a network with a central database. (4)
Implementing regular screening for CKD in patients with
diabetes mellitus and hypertension. (5) Referring pa-
tients with CKD to an appropriate setup for planning
management. (6) Educating medical personnel about the
algorithmic approach for the management of patients
with CKD at the community health center level, par-
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Abbreviations are: MPW, multipurpose worker; MO, medical officer.
ticularly the appropriate use of angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers.
With this approach, we are likely to fulfill the following
short-term objectives of: making people aware of CKD
and its importance; finding the prevalence of CKD and its
major causes in India in community-based studies; show-
ing the impact of screening high-risk individuals to the
community and policy makers.
Once the short-term objectives have been met, it will
then be easy to convince policy makers to implement a
prevention program using a wider network of the exist-
ing health care structure of the country. In India, there is
an existing health care system both for the rural as well
as for the urban community. However, it is better estab-
lished for the rural population than the urban population
(Table 1) [21]. In urban areas, in addition to central gov-
ernment health services, there are other organizations
like railways, the Municipal Corporation, and so forth,
which are running their own dispensaries and hospitals
as per the need of their own organizations. We have to
redeem such an existing health care system in a better
way for prevention programs like one for CKD. For the
first time in India, the National Health Policy 2002, in
addition to other objectives, made one of its objectives
to “establish a baseline estimate for non-communicable
diseases,” which was never an issue in previous health
policies [21].
Finally, the key issue of funding the program needs
to be explored. Mani [1], in his community-based pro-
gram, has shown that by using cheaper medicines for
controlling blood pressure and diabetes, blood pressure
can be less than 140/90 mm Hg in 96% cases and can
bring glycated hemoglobin levels to 7% or less in 50%
of patients. By using local health care workers, the an-
nual cost of the treatment program was US $.27 cents per
capita. Overall, it looks quite encouraging. But whether
the same program can be organized and sustained in the
whole country is questionable. This requires, in addition
to commitment of physician fraternity, a political will for
prevention of CKD, which, in my opinion, is significantly
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lacking at present. Currently in India, CKD is not a pri-
ority for the government at all, and initial funding has to
come from international agencies like the World Health
Organization, World Bank, and International Society of
Nephrology (just as in the case of acquired immune de-
ficiency syndrome and noncommunicable diseases like
cardiovascular diseases, polio eradication, and so forth).
The concept of a “global fund” for CKD, an idea that
Schieppati et al have discussed, is still to be accepted
[22]. Further, once the prevention program has started
and established to some degree, the existing system of
health care needs to be used for the prevention program
for CKD also.
To conclude, CKD/ESRD is a major problem for India,
and with increasing diabetes burden, it is going to increase
further. Managing the whole population of these patients
will be impossible for India, where many other issues are
of more priority than CKD. However, money invested
now in establishing a prevention program for CKD in
India is certainly going to give results in years to come
and, ultimately, in the long-run will still be cost effective.
Then the saved money can be used for other health care
programs. But, in my opinion, this idea will not be easy to
impress on current policy makers and the political system
of this country.
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